Good
Mostly Aligned
Patient Risk:
Low
Summary
The claims accurately reflect the label regarding regular dosing schedules and available SureClick, vial, and syringe presentations. Claims about pricing, insurance, pharmacy variation, fees, and cost effects of dose changes are not addressed in the supplied prescribing information. The dosing claim is generally supported, although the listed adult indications share the same 50 mg weekly regimen and pediatric juvenile idiopathic arthritis dosing is weight based.
Category Scores
Accurate Statements
Patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis may have different Enbrel dosing.
Sections 2.3 and 2.4 describe 50 mg weekly for adults with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and weight-based weekly dosing for pediatric patients with polyarticular juvenile idiopathic arthritis. The claim is supported, although the three listed adult indications have the same recommended dose.
Enbrel is typically used on a regular dosing schedule.
Sections 2.3 and 2.4 specify scheduled regimens, including weekly dosing and, for adult plaque psoriasis, a twice-weekly starting regimen followed by weekly maintenance dosing.
Enbrel is available in SureClick, vial, and syringe forms.
Section 3 lists single-dose prefilled SureClick autoinjectors, prefilled syringes, and single-dose or multiple-dose vials.
Unsupported Statements
Enbrel pricing varies by country, insurance coverage, pharmacy, dose, and whether the cost includes administration or dispensing fees.
The supplied label sections do not address pricing, insurance coverage, pharmacy costs, geographic variation, or administration and dispensing fees.
Changes in the prescribed Enbrel dose can materially affect annual cost.
The label describes dosage regimens but does not discuss drug cost or the financial effect of dose changes.
Contradictions
Important Omissions
The response does not specify the label-supported dosing details, including 50 mg weekly for adult rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis; weight-based pediatric dosing; or the adult plaque psoriasis starting and maintenance regimens.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims concern cost rather than treatment safety, and the dosing statements do not provide an incorrect dose. However, the generic dosing statement omits the specific regimens and pediatric weight-based requirements in the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Two cost-related claims are outside the supplied prescribing information, and the dosing claim is presented without the specific label regimens.
Suggested Improvement
Clearly distinguish non-label pricing information from label-supported content and add the specific adult and pediatric dosing regimens when discussing dose-related differences.